ANI Has Four-Pillar Growth Strategy Following Novitium Deal
As Company Sees Q4 Revenue Increase On The Back Of Generics Sales
Executive Summary
With a four-pillar growth strategy, ANI Pharma plans over 25 product launches in 2021 and 2022. With the recent acquisition of Novitium the company is also advancing three 505(b)(2) candidates in oncology and hypertension, after seeing a slight growth in overall revenues and generics sales in 2020.
You may also be interested in...
ANI Pharmaceuticals Completes $210m Novitium Acquisition
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.
ANI Prepares For Cortrophin Launch
US-based ANI Pharmaceuticals is looking to strengthen its leadership team and strategize a commercial approach for the launch of Cortrophin Gel, as it anticipates FDA approval by 29 October 2021. ANI reported a 2.4% increase in its generics business.
ANI Transforms With Novitium And Sandoz Deals
US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches.